JIPOAd
ESID
  • Users Online: 240
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most popular articles (Since November 13, 2017)

 
 
  Archives   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EDITORIAL
Being realistic and optimistic in curing cancer
Aung Naing
October-December 2018, 1(2):53-55
DOI:10.4103/JIPO.JIPO_20_18  
  1,976 407 4
REVIEW ARTICLES
Pneumonitis after precision oncology therapies: A concise review
Akash Jain, Vickie R Shannon, Ajay Sheshadri
July-September 2018, 1(1):26-37
DOI:10.4103/JIPO.JIPO_9_18  
  2,051 287 -
ORIGINAL ARTICLES
Erlotinib in patients with advanced non-small cell lung cancer in Middle Eastern population
Abdul Rahman Jazieh, Turki M Fayea, Mervat Mahrous, Tarek Darwish, Essam Fawzi, Ashwaq A Alolayan, Nagham Sheblaq, Mohammed Alkaiyat, Yosra Ali
July-September 2018, 1(1):19-25
DOI:10.4103/JIPO.JIPO_2_18  
  1,837 130 -
REVIEW ARTICLES
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Abdulrazzak Zarifa, Mohammed Salih, Juan Lopez-Mattei, Hun Ju Lee, Cezar Iliescu, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Elie Mouhayar, Joseph Kim, Peter Kim
October-December 2018, 1(2):68-77
DOI:10.4103/JIPO.JIPO_15_18  
  1,631 219 1
ORIGINAL ARTICLES
The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes
Hamzah Abu-Sbeih, Tenglong Tang, Faisal Shaukat Ali, Daniel Hartman Johnson, Wei Qiao, Adi Diab, Yinghong Wang
July-September 2018, 1(1):7-18
DOI:10.4103/JIPO.JIPO_12_18  
  1,459 224 1
REVIEW ARTICLES
Understanding the toxicity of cancer immunotherapies: Use of patient-reported outcomes
Tito R Mendoza
July-September 2018, 1(1):38-45
DOI:10.4103/JIPO.JIPO_10_18  
  1,295 213 -
ORIGINAL ARTICLE
The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
Abdul Rahman Jazieh, Adda Bounedjar, Fouad Al Dayel, Shamayel Fahem, Arafat Tfayli, Kakil Rasul, Hassan Jaafar, Mohammad Jaloudi, Turki Al Fayea, Hatim Q Al Maghrabi, Hanaa Bamefleh, Khaled Al Kattan, Blaha Larbaoui, Taha Filali, Hamed Al Husaini, Yosra Ali, in collaboration with the Arab Collaborative Hematology Oncology Group (ACHOG)
January-March 2019, 2(1):4-7
DOI:10.4103/JIPO.JIPO_22_18  
  1,373 89 2
ORIGINAL ARTICLES
Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series
David D Stenehjem, Courtney C Cavalieri, Eric Swanson, Benjamin Solomon, Jonathan Whisenant, Dao Tran, John Weis, G Weldon Gilcrease, Sunil Sharma, Ignacio Garrido-Laguna
July-September 2018, 1(1):1-6
DOI:10.4103/JIPO.JIPO_5_18  
  1,302 146 -
REVIEW ARTICLES
Personalized cancer immunotherapy: Today's challenge and tomorrow's promise
Malaka Ameratunga, Wen Xu, Juanita Lopez
October-December 2018, 1(2):56-67
DOI:10.4103/JIPO.JIPO_13_18  
  1,166 156 -
EDITORIAL
Optimizing Precision Oncology and Immunotherapy Strategies: Moving into the Next Stage of Cancer Medicine
Phoebe Lewis, Timothy A Yap
January-March 2019, 2(1):1-3
DOI:10.4103/JIPO.JIPO_26_18  
  1,001 165 -
REVIEW ARTICLE
Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials
Haelee M Chin, David K Lai, Gerald S Falchook
January-March 2019, 2(1):10-16
DOI:10.4103/JIPO.JIPO_17_18  
  911 160 1
CASE REPORTS
Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab
Shelby L Kubicki, Macartney E Welborn, Anisha B Patel
October-December 2018, 1(2):78-81
DOI:DOI: 10.4103/JIPO.JIPO_7_18  
  893 108 -
Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab
Amulya Balagani, Muhammad H Arain, Ajay Sheshadri
July-September 2018, 1(1):49-52
DOI:10.4103/JIPO.JIPO_8_18  
  868 81 -
Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy
Macartney E Welborn, Shelby L Kubicki, Anisha B Patel
October-December 2018, 1(2):82-84
DOI:10.4103/JIPO.JIPO_11_18  
  712 85 -
REVIEW ARTICLES
Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs
Elena Cojocaru, Mariana Scaranti, Anna Minchom
April-June 2019, 2(2):23-35
DOI:10.4103/JIPO.JIPO_24_18  
  655 140 -
COMMENTARY
Opening new boundaries in biomarker detection: Awakening of middle east and North Africa Region
Christian Rolfo, Umberto Malapelle
January-March 2019, 2(1):8-9
DOI:10.4103/JIPO.JIPO_27_18  
  675 73 -
EDITORIAL
Moonshot for precision medicine
Jordi Rodon
April-June 2019, 2(2):21-22
DOI:10.4103/JIPO.JIPO_4_19  
  653 95 -
CASE REPORTS
Inflammatory colitis after treatment of melanoma with talimogene laherparepvec (T-VEC)
Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson
July-September 2018, 1(1):46-48
DOI:10.4103/JIPO.JIPO_3_18  
  674 52 -
CASE REPORT
Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang
April-June 2019, 2(2):40-45
DOI:10.4103/JIPO.JIPO_18_18  
  553 119 -
REVIEW ARTICLES
Should we design clinical trials differently in the era of cancer immunotherapy?
Chia-Chi Lin
April-June 2019, 2(2):36-39
DOI:10.4103/JIPO.JIPO_5_19  
  543 87 1
SPECIAL ARTICLE
5th Annual immuno-oncology 360° conference: What to expect
Kate Woda
January-March 2019, 2(1):17-18
DOI:10.4103/2590-017X.249502  
  499 83 -
5th Annual immuno-oncology 360° conference: Spanning science and business to bring new therapies to patients
Marie Recine
April-June 2019, 2(2):46-51
DOI:10.4103/JIPO.JIPO_6_19  
  493 74 -
CASE REPORT
MET receptor amplification drives resistance to Anti-EGFR therapies
Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_7_19  
  170 5 -
REVIEW ARTICLE
Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review
Ahmad Daher, Carlos Kamiya Matsuoka, Monica Elena Loghin, Marta Penas-Prado, Sudhakar Tummala
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_3_19  
  156 14 -
CASE REPORT
Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer
Yacine Wissam, Laila Belcaid, Ruth Wittoek, Vanessa Smith, Amber Vanhaecke, Sofie De Schepper, Lennart Jans, Daphné t'Kint de Roodenbeke, Andrea Gombos, Sandrine Aspeslagh
0, 0(0):0-0
DOI:10.4103/JIPO.JIPO_8_19  
  44 4 -